General Statement of Disclosure:
CONSULTING FEES/HONORARIA: Novo Nordisk Inc.(SIGNIFICANT), Oruka(MODEST), Oruka (MODEST) OTHER FINANCIAL BENEFIT: Kiniksa Pharmaceuticals (SIGNIFICANT)
CONSULTING FEES/HONORARIA: Novo Nordisk Inc.(SIGNIFICANT), Oruka(MODEST), Oruka (MODEST) OTHER FINANCIAL BENEFIT: Kiniksa Pharmaceuticals (SIGNIFICANT)
© 2025 American College of Cardiology Foundation. All rights reserved.
